(Q54675660)

English

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

scientific article published on 8 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

phase I clinical trial

0 references

object named as

David W Hedley

8

0 references

author name string

Benoit You

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Anthony Brade

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Joao M Magalhaes

3

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Lillian L Siu

4

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Amit Oza

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Sonya Lovell

6

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Lisa Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Leonardo V Nicacio

9

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Eric X Chen

10

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

publication date

8 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

29

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

996-1003

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

https://scigraph.springernature.com/pub.10.1007/s10637-010-9444-0

0 references

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Quantitative image analysis of immunohistochemical stains using a CMYK color model

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

The impact of tissue fixatives on morphology and antibody-based protein profiling in tissues and cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9444-0

21 January 2018

Targeted therapies in the treatment of colorectal cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Phase II clinical trial of h-R3 combined radiotherapy for locoregionally advanced nasopharyngeal carcinoma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20454832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9444-0

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20454832

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54675660&oldid=1749511472"